{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T01:13:37Z","timestamp":1791249217846,"version":"4.1.0"},"reference-count":47,"publisher":"Public Library of Science (PLoS)","issue":"4","license":[{"start":{"date-parts":[[2011,4,14]],"date-time":"2011-04-14T00:00:00Z","timestamp":1302739200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0018583","type":"journal-article","created":{"date-parts":[[2011,4,14]],"date-time":"2011-04-14T20:51:27Z","timestamp":1302814287000},"page":"e18583","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":102,"title":["A Systematic Study of Gene Mutations in Urothelial Carcinoma; Inactivating Mutations in TSC2 and PIK3R1"],"prefix":"10.1371","volume":"6","author":[{"given":"Gottfrid","family":"Sj\u00f6dahl","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Lauss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sigurdur","family":"Gudjonsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fredrik","family":"Liedberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christer","family":"Halld\u00e9n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunilla","family":"Chebil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wiking","family":"M\u00e5nsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mattias","family":"H\u00f6glund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Lindgren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2011,4,14]]},"reference":[{"issue":"23","key":"ref1","first-page":"8108","article-title":"FGFR3 and TP53 gene mutations define two distinct pathways in urothelial cell carcinoma of the bladder.","volume":"1;63","author":"AA Bakkar","year":"2003","journal-title":"Cancer Res"},{"issue":"6","key":"ref2","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1158\/0008-5472.CAN-03-2421","article-title":"FGFR3 and P53 characterize alternative genetic pathways in the pathogenesis of urothelial cell carcinoma.","volume":"15;64","author":"BW van Rhijn","year":"2004","journal-title":"Cancer Res"},{"issue":"9","key":"ref3","doi-asserted-by":"crossref","first-page":"3463","DOI":"10.1158\/0008-5472.CAN-09-4213","article-title":"Combined gene expression and genomic profiling define two intrinsic molecular subtypes of urothelial carcinoma and gene signatures for molecular grading and outcome.","volume":"1;70","author":"D Lindgren","year":"2010","journal-title":"Cancer Res"},{"issue":"19","key":"ref4","doi-asserted-by":"crossref","first-page":"6008","DOI":"10.1158\/1078-0432.CCR-09-0898","article-title":"Spectrum of phosphatidylinositol 3-kinase pathway gene alterations in bladder cancer.","volume":"1;15","author":"FM Platt","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"5","key":"ref5","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1016\/j.juro.2009.01.011","article-title":"Activation of RAS family genes in urothelial carcinoma.","volume":"181","author":"I Boulalas","year":"2009","journal-title":"J Urol"},{"issue":"1","key":"ref6","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1177\/172460080902400103","article-title":"Mutational analysis of the BRAF gene in transitional cell carcinoma of the bladder.","volume":"24","author":"I Boulalas","year":"2009","journal-title":"Int J Biol Markers"},{"issue":"1","key":"ref7","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1038\/onc.2009.315","article-title":"AKT1 mutations in bladder cancer: identification of a novel oncogenic mutation that can co-operate with E17K.","volume":"7;29","author":"JM Askham","year":"2010","journal-title":"Oncogene"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1755-8794-1-3","article-title":"Tiling resolution array CGH and high density expression profiling of urothelial carcinomas delineate genomic amplicons and candidate target genes specific for advanced tumors.","volume":"31;1","author":"M Heidenblad","year":"2008","journal-title":"BMC Med Genomics"},{"issue":"56","key":"ref9","doi-asserted-by":"crossref","first-page":"6680","DOI":"10.1038\/sj.onc.1204091","article-title":"The rapamycin-sensitive signal transduction pathway as a target for cancer therapy.","volume":"27;19","author":"M Hidalgo","year":"2000","journal-title":"Oncogene"},{"issue":"24","key":"ref10","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.4161\/cbt.8.24.10296","article-title":"The role of mTOR in bladder cancer.","volume":"8","author":"KM Gust","year":"2009","journal-title":"Cancer Biol Ther"},{"issue":"6","key":"ref11","doi-asserted-by":"crossref","first-page":"3062","DOI":"10.2353\/ajpath.2010.090872","article-title":"Mammalian Target of Rapamycin (mTOR) Regulates Cellular Proliferation and Tumor Growth in Urothelial Carcinoma.","volume":"176","author":"DE Hansel","year":"2010","journal-title":"Am J Pathol"},{"issue":"1","key":"ref12","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1002\/ijc.23917","article-title":"Somatic mutations of adenomatous polyposis coli gene and nuclear b-catenin accumulation have prognostic significance in invasive urothelial carcinomas: evidence for Wnt pathway implication.","volume":"1;124","author":"E Kastritis","year":"2009","journal-title":"Int J Cancer"},{"issue":"5","key":"ref13","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1016\/S0022-5347(05)64359-5","article-title":"Beta-catenin mutations correlate with over expression of C-myc and cyclin D1 Genes in bladder cancer.","volume":"168","author":"H Shiina","year":"2002","journal-title":"J Urol"},{"issue":"12","key":"ref14","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1046\/j.1440-1827.2000.01139.x","article-title":"Aberrant expression of beta-catenin and mutation of exon 3 of the beta-catenin gene in renal and urothelial carcinomas.","volume":"50","author":"X Zhu","year":"2000","journal-title":"Pathol Int"},{"issue":"4","key":"ref15","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/nmeth0410-248","article-title":"A method and server for predicting damaging missense mutations.","volume":"Apr;7","author":"IA Adzhubei","year":"2010","journal-title":"Nat Methods"},{"issue":"22","key":"ref16","doi-asserted-by":"crossref","first-page":"3664","DOI":"10.1200\/JCO.2005.05.1771","article-title":"Prospective study of FGFR3 mutations as a prognostic factor in nonmuscle invasive urothelial bladder carcinomas.","volume":"1;24","author":"S Hern\u00e1ndez","year":"2006","journal-title":"J Clin Oncol"},{"issue":"10","key":"ref17","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1200\/JCO.2003.05.073","article-title":"Molecular grading of urothelial cell carcinoma with fibroblast growth factor receptor 3 and MIB-1 is superior to pathologic grade for the prediction of clinical outcome.","volume":"15;21","author":"BW Van Rhijn","year":"2003","journal-title":"J Clin Oncol"},{"issue":"11","key":"ref18","doi-asserted-by":"crossref","first-page":"e13821","DOI":"10.1371\/journal.pone.0013821","article-title":"FGFR3, HRAS, KRAS, NRAS and PIK3CA Mutations in Bladder Cancer and Their Potential as Biomarkers for Surveillance and Therapy.","volume":"3;5","author":"LC Kompier","year":"2010","journal-title":"PLoS One"},{"issue":"16","key":"ref19","doi-asserted-by":"crossref","first-page":"5049","DOI":"10.1158\/1078-0432.CCR-09-0632","article-title":"PIK3CA mutation associates with improved outcome in breast cancer.","volume":"15;15","author":"K Kalinsky","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"15","key":"ref20","doi-asserted-by":"crossref","first-page":"7401","DOI":"10.1158\/0008-5472.CAN-06-1182","article-title":"PIK3CA Mutations Are an Early Genetic Alteration Associated with FGFR3 Mutations in Superficial Papillary Bladder Tumors.","volume":"66","author":"E Lopez-Knowles","year":"2006","journal-title":"Cancer Res"},{"issue":"33","key":"ref21","doi-asserted-by":"crossref","first-page":"5218","DOI":"10.1038\/sj.onc.1208705","article-title":"FGFR3 and Ras gene mutations are mutually exclusive genetic events in urothelial cell carcinoma.","volume":"4;24","author":"AH Jebar","year":"2005","journal-title":"Oncogene"},{"issue":"6","key":"ref22","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1097\/01.cmr.0000232300.22032.86","article-title":"NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing.","volume":"16","author":"E Edlundh\u2013Rose","year":"2006","journal-title":"Melanoma Res"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1038\/ng2078","article-title":"Germline gain-of-function mutations in RAF1 cause Noonan syndrome.","volume":"39","author":"MA Razzaque","year":"2007","journal-title":"Nat Genet"},{"issue":"10","key":"ref24","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1136\/jmg.2010.078964","article-title":"Germline APC mutation spectrum derived from 863 genomic variations identified through a 15-year medical genetics service to French patients with FAP.","volume":"47","author":"A Lagarde","year":"2010","journal-title":"J Med Genet"},{"issue":"7","key":"ref25","doi-asserted-by":"crossref","first-page":"2554","DOI":"10.1158\/0008-5472-CAN-04-3913","article-title":"PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma.","volume":"1;65","author":"LH Saal","year":"2005","journal-title":"Cancer Res"},{"issue":"8","key":"ref26","first-page":"1477","article-title":"PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas.","volume":"17;24","author":"JW Lee","year":"2005","journal-title":"Oncogene"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1146\/annurev.pathol.4.110807.092311","article-title":"PTEN and the PI3-kinase pathway in cancer.","volume":"4","author":"N Chalhoub","year":"2009","journal-title":"Annu Rev Pathol"},{"issue":"6","key":"ref28","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.ccr.2009.10.016","article-title":"Somatic mutations in p85alpha promote tumorigenesis through class IA PI3K activation.","volume":"8;16","author":"BS Jaiswal","year":"2009","journal-title":"Cancer Cell"},{"issue":"24","key":"ref29","doi-asserted-by":"crossref","first-page":"3215","DOI":"10.1038\/sj.onc.1201855","article-title":"Point mutation and homozygous deletion of PTEN\/MMAC1 in primary bladder cancers.","volume":"18;16","author":"P Cairns","year":"1998","journal-title":"Oncogene"},{"issue":"5\u20136","key":"ref30","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1038\/sj.bjc.6690439","article-title":"Somatic mutation of PTEN in bladder carcinoma.","volume":"80","author":"JS Aveyard","year":"1999","journal-title":"Br J Cancer"},{"issue":"6","key":"ref31","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1101\/gad.1772909","article-title":"Inactivation of p53 and Pten promotes invasive bladder cancer.","volume":"15;23","author":"AM Puzio-Kuter","year":"2009","journal-title":"Genes Dev"},{"issue":"13","key":"ref32","doi-asserted-by":"crossref","first-page":"5305","DOI":"10.1158\/0008-5472.CAN-09-3399","article-title":"The phosphoinositide 3-kinase regulatory subunit p85alpha can exert tumor suppressor properties through negative regulation of growth factor signaling.","volume":"1;70","author":"CM Taniguchi","year":"2010","journal-title":"Cancer Res"},{"issue":"5897","key":"ref33","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1126\/science.1164382","article-title":"An integrated genomic analysis of human glioblastoma multiforme.","volume":"26;321","author":"DW Parsons","year":"2008","journal-title":"Science"},{"issue":"4A","key":"ref34","first-page":"2675","article-title":"Low-frequency mutation of Ha-ras and Ki-ras oncogenes in transitional cell carcinoma of the bladder.","volume":"18","author":"G Older\u00f8y","year":"1998","journal-title":"Anticancer Res"},{"issue":"3","key":"ref35","first-page":"497","article-title":"Screening of human bladder carcinomas for the presence of Ha-ras codon 12 mutation.","volume":"7","author":"N Cattan","year":"2000","journal-title":"Oncol Rep"},{"issue":"1","key":"ref36","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0165-4608(00)00223-5","article-title":"H-RAS, K-RAS, and N-RAS gene activation in human bladder cancers.","volume":"121","author":"B Przybojewska","year":"2000","journal-title":"Cancer Genet Cytogenet"},{"issue":"5","key":"ref37","first-page":"905","article-title":"No evidence for involvement of beta-catenin and APC in urothelial carcinomas.","volume":"20","author":"R Stoehr","year":"2002","journal-title":"Int J Oncol"},{"issue":"19","key":"ref38","first-page":"7101","article-title":"Alterations of beta- and gamma-catenin in N-butyl-N-(-4-hydroxybutyl)nitrosamine-induced murine bladder cancer.","volume":"1;61","author":"H Shiina","year":"2001","journal-title":"Cancer Res"},{"issue":"2","key":"ref39","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s00726-004-0119-z","article-title":"Proteins interacting with the tuberous sclerosis gene products.","volume":"Oct;27","author":"M Rosner","year":"2004","journal-title":"Amino Acids"},{"issue":"5","key":"ref40","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/j.cell.2006.06.055","article-title":"TSC2 integrates Wnt and energy signals via a coordinated phosphorylation by AMPK and GSK3 to regulate cell growth.","volume":"8;126","author":"K Inoki","year":"2006","journal-title":"Cell"},{"issue":"3","key":"ref41","doi-asserted-by":"crossref","first-page":"C836","DOI":"10.1152\/ajpcell.00554.2007","article-title":"A GSK-3\/TSC2\/mTOR pathway regulates glucose uptake and GLUT1 glucose transporter expression.","volume":"295","author":"CL Buller","year":"2008","journal-title":"Am J Physiol Cell Physiol"},{"issue":"8","key":"ref42","doi-asserted-by":"crossref","first-page":"5947","DOI":"10.1074\/jbc.C200473200","article-title":"The tuberin-hamartin complex negatively regulates beta-catenin signaling activity.","volume":"21;278","author":"BC Mak","year":"2003","journal-title":"J Biol Chem"},{"issue":"2","key":"ref43","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1158\/0008-5472.CAN-09-2340","article-title":"Beyond rapalog therapy: preclinical pharmacology and antitumor activity of WYE-125132, an ATP-competitive and specific inhibitor of mTORC1 and mTORC2.","volume":"15;70","author":"K Yu","year":"2010","journal-title":"Cancer Res"},{"issue":"6","key":"ref44","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1158\/1535-7163.MCT-07-2408","article-title":"Mammalian target of rapamycin inhibition as a therapeutic strategy in the management of urologic malignancies.","volume":"7","author":"JA Garcia","year":"2008","journal-title":"Mol Cancer Ther"},{"issue":"12","key":"ref45","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1158\/1940-6207.CAPR-09-0169","article-title":"Intravesical delivery of rapamycin suppresses tumorigenesis in a mouse model of progressive bladder cancer.","volume":"2","author":"CM Seager","year":"2009","journal-title":"Cancer Prev Res"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1186\/1471-2407-8-176","article-title":"Rapamycin delays growth of Wnt-1 tumors in spite of suppression of host immunity.","volume":"21;8","author":"EV Svirshchevskaya","year":"2008","journal-title":"BMC Cancer"},{"issue":"2","key":"ref47","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.canlet.2009.09.015","article-title":"mTOR inhibitor rapamycin alone or combined with cisplatin inhibits growth of esophageal squamous cell carcinoma in nude mice.","volume":"28;290","author":"G Hou","year":"2010","journal-title":"Cancer Lett"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0018583","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,8]],"date-time":"2020-05-08T21:02:03Z","timestamp":1588971723000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0018583"}},"subtitle":[],"editor":[{"given":"Xin-yuan","family":"Guan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2011,4,14]]},"references-count":47,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2011,4,14]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0018583","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,4,14]]}}}